Literature DB >> 7516275

Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model.

D A Hart1, P Whidden, F Green, J Henkin, D E Woods.   

Abstract

Pulmonary fibrosis was induced in male Sprague-Dawley rats by intratracheal instillation of bleomycin. By 30 d post-bleomycin, the lungs exhibited elevated interstitial collagen levels. Thirty d after exposure to bleomycin, animals were further treated by intratracheal administration of phosphate-buffered saline (PBS) or 12,500 units of recombinant human urokinase (rh-UK). Three days later, the animals were sacrificed and the lungs fixed, sectioned, and assessed for fibrosis. The presence of interstitial collagen was quantitated using a BioQuant Image Analysis System (R and M Biometrics, Inc., Nashville, TN). Urokinase treatment of animals with established pulmonary fibrosis induced by exposure to 0.5 units of bleomycin was found to diminish the collagen content of lungs to near control levels by 3 d post-UK treatment. By 36 d post-UK treatment (66 d post-bleomycin), values for interstitial collagen were again partially elevated, indicating that UK treatment interfered with established fibrosis but did not stop the bleomycin-mediated process. However, the extent of fibrosis was less than that observed in lungs from non-UK treated animals 66 d post-bleomycin. UK treatment initiated 63 d post-bleomycin exposure again revealed a decline in the extent of fibrosis, but the values did not return to baseline levels. A repeat of the short-term experiment with a higher dose of bleomycin (0.85 units) again revealed that UK treatment was effective in diminishing the extent of fibrosis from 22% to 12% collagen. These results indicate that exogenous UK may be an effective therapeutic modality in the treatment of pulmonary fibrosis induced by some stimuli or developing in association with diseases such as scleroderma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516275

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  11 in total

Review 1.  Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation.

Authors:  Ramalinga Kuruba; Annette Wilson; Xiang Gao; Song Li
Journal:  AAPS J       Date:  2009-01-09       Impact factor: 4.009

2.  Urokinase Plasminogen Activator Overexpression Reverses Established Lung Fibrosis.

Authors:  Jeffrey C Horowitz; Daniel J Tschumperlin; Kevin K Kim; John J Osterholzer; Natalya Subbotina; Iyabode O Ajayi; Seagal Teitz-Tennenbaum; Ammara Virk; Megan Dotson; Fei Liu; Delphine Sicard; Shijing Jia; Thomas H Sisson
Journal:  Thromb Haemost       Date:  2019-11-08       Impact factor: 5.249

3.  Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.

Authors:  N Hattori; J L Degen; T H Sisson; H Liu; B B Moore; R G Pandrangi; R H Simon; A F Drew
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

4.  Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury.

Authors:  C Barazzone; D Belin; P F Piguet; J D Vassalli; A P Sappino
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

5.  The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.

Authors:  C M Swaisgood; E L French; C Noga; R H Simon; V A Ploplis
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 6.  Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome.

Authors:  Sara C Sebag; Julie A Bastarache; Lorraine B Ware
Journal:  Curr Pharm Biotechnol       Date:  2011-09       Impact factor: 2.837

7.  Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

Authors:  D T Eitzman; R D McCoy; X Zheng; W P Fay; T Shen; D Ginsburg; R H Simon
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

Review 8.  Urokinase and its receptors in chronic kidney disease.

Authors:  Guoqiang Zhang; Allison A Eddy
Journal:  Front Biosci       Date:  2008-05-01

Review 9.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Authors:  Antje Moeller; Kjetil Ask; David Warburton; Jack Gauldie; Martin Kolb
Journal:  Int J Biochem Cell Biol       Date:  2007-08-30       Impact factor: 5.085

10.  The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism.

Authors:  Noboru Hattori; Shinya Mizuno; Yuka Yoshida; Kazuo Chin; Michiaki Mishima; Thomas H Sisson; Richard H Simon; Toshikazu Nakamura; Masayuki Miyake
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.